Evidence map›Paper›PMID 30585359›Full record

ArticleGlia2019

Low sulfated heparins target multiple proteins for central nervous system repair.

George A McCanney, Michael A McGrath, Thomas D Otto, Richard Burchmore, Edwin A Yates, Charles D Bavington, Hugh J Willison, Jeremy E Turnbull, Susan C Barnett

Open access · hybridAbstract read
In one paragraph

Article in Glia, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
1.1field-weighted citation impact, top 25% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 20 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 2 countries.

George A McCanneyInstitute of Infection, Immunity, and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Michael A McGrathInstitute of Infection, Immunity, and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Thomas D OttoInstitute of Infection, Immunity, and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Richard BurchmoreInstitute of Infection, Immunity, and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Edwin A YatesDepartment of Biochemistry, Institute of Integrative Biology, University of Liverpool, Liverpool, UK.
Charles D BavingtonGlycoMar Limited, European Centre for Marine Biotechnology, Dunstaffnage Marine Laboratory, Oban, Argyll, Scotland, UK.
Hugh J WillisonInstitute of Infection, Immunity, and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.
Jeremy E TurnbullDepartment of Biochemistry, Institute of Integrative Biology, University of Liverpool, Liverpool, UK.
Susan C BarnettInstitute of Infection, Immunity, and Inflammation, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.ORCID 0000-0003-1009-0575
Wellcome Centre for Molecular Parasitology · GBUniversity of Liverpool · GBGlycoMar (United Kingdom) · GB

Funding

Chief Scientist Office ETM/439Wellcome Trust 202789/Z/16/Z
6 · The paper itself

Abstract

The lack of endogenous repair following spinal cord injury (SCI) accounts for the frequent permanent deficits for which effective treatments are absent. Previously, we demonstrated that low sulfated modified heparin mimetics (LS-mHeps) attenuate astrocytosis, suggesting they may represent a novel therapeutic approach. mHeps are glycomolecules with structural similarities to resident heparan sulfates (HS), which modulate cell signaling by both sequestering ligands, and acting as cofactors in the formation of ligand-receptor complexes. To explore whether mHeps can affect the myelination and neurite outgrowth necessary for repair after SCI, we created lesioned or demyelinated neural cell co-cultures and exposed them with a panel of mHeps with varying degrees and positions of their sulfate moieties. LS-mHep7 enhanced neurite outgrowth and myelination, whereas highly sulfated mHeps (HS-mHeps) had attenuating effects. LS-mHeps had no effects on myelination or neurite extension in developing, uninjured myelinating cultures, suggesting they might exert their proregenerating effects by modulating or sequestering inhibitory factors secreted after injury. To investigate this, we examined conditioned media from cultures using chemokine arrays and conducted an unbiased proteomics approach by applying TMT-LC/MS to mHep7 affinity purified conditioned media from these cultures. Multiple protein factors reported to play a role in damage or repair mechanisms were identified, including amyloid betaA4. Amyloid beta peptide (1-42) was validated as an important candidate by treating myelination cultures and shown to inhibit myelination. Thus, we propose that LS-mHeps exert multiple beneficial effects on mechanisms supporting enhanced repair, and represent novel candidates as therapeutics for CNS damage.

Indexed as

Amyloid beta-PeptidesAnimalsAnimals, NewbornAntimetabolitesCell ProliferationCells, CulturedCentral Nervous System DiseasesCulture Media, ConditionedCytokinesDemyelinating DiseasesDeoxyuridineEmbryo, MammalianHeparan SulfateIntercellular Signaling Peptides and ProteinsMyelin-Oligodendrocyte GlycoproteinMyelin ProteinsAmyloid beta-PeptidesAntimetabolitesCulture Media, ConditionedCytokinesDeoxyuridineHeparan SulfateIntercellular Signaling Peptides and ProteinsMyelin-Oligodendrocyte GlycoproteinMyelin Proteinsamyloid-βheparan sulfatesmyelinationneurite outgrowth

Identifiers

PMID30585359
PMCPMC6492281
OpenAlexW2903927900

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.